Finally, transcriptional repression by targeting CDK12 has been suggested as a encouraging strategy to impede the progresssion of cancers with no definitive drivers, such as triple negative breast cancer (TNBC)15 and osteosarcoma.1 The gene discussed is CDK12; the disease is cancer.